Antibiotic-resistant Klebsiella pneumoniae and Escherichia coli high-risk clones and an IncFII(k) mosaic plasmid hosting Tn1 (blaTEM-4) in isolates from 1990 to 2004

We describe the genetic background of bla(TEM-4) and the complete sequence of pRYC11::bla(TEM-4), a mosaic plasmid that is highly similar to pKpQIL-like variants, predominant among TEM-4 producers in a Spanish hospital (1990 to 2004), which belong to Klebsiella pneumoniae and Escherichia coli high-risk clones responsible for the current spread of different antibiotic resistance genes. Predominant populations of plasmids and host adapted clonal lineages seem to have greatly contributed to the spread of resistance to extended-spectrum cephalosporins.

Klebsiella pneumoniae sequence type 11 from companion animals bearing ArmA methyltransferase, DHA-1 β-lactamase, and QnrB4

Seven Klebsiella pneumoniae isolates from dogs and cats in Spain were found to be highly resistant to aminoglycosides, and ArmA methyltransferase was responsible for this phenotype. All isolates were typed by multilocus sequence typing (MLST) as ST11, a human epidemic clone reported worldwide and associated with, among others, OXA-48 and NDM carbapenemases. In the seven strains, armA was borne by an IncR plasmid, pB1025, of 50 kb. The isolates were found to coproduce DHA-1 and SHV-11 β-lactamases, as well as the QnrB4 resistance determinant. This first report of the ArmA methyltransferase in pets illustrates their importance as a reservoir for human multidrug-resistant K. pneumoniae.

Polymyxin resistance caused by mgrB inactivation is not associated with significant biological cost in Klebsiella pneumoniae

The inactivation of the mgrB gene, which encodes a negative-feedback regulator of the PhoPQ signaling system, was recently shown to be a common mutational mechanism responsible for acquired polymyxin resistance among carbapenemase-producing Klebsiella pneumoniae strains from clinical sources. In this work, we show that mgrB mutants can easily be selected in vitro from different K. pneumoniae lineages, and mgrB inactivation is not associated with a significant biological cost.

Enterobacterias productoras de carbapenemasas: tipos, epidemiología molecular y alternativas terapéuticas

Los carbapenémicos son los antibióticos β-lactámicos de más amplio espectro activos frente a microorganismos grampositivos, gramnegativos y anaerobios. Estos agentes mantienen su actividad frente a enterobacterias productoras de β-lactamasas de espectro extendido (BLEE) o de cefalosporinasas AmpC. Dentro de las enterobacterias, la resistencia a los carbapenémicos está mediada principalmente por la producción de diferentes tipos de carbapenemasas, aunque esta resistencia también puede ser debida a una combinación pérdida de porinas más enzimas BLEE o una hiperexpresión de AmpC. Las carbapenemasas representan la familia de β-lactamasas más versátil, con un amplio espectro. La mayoría de estas enzimas reconocen e hidrolizan a casi todos los β- lactámicos y son resistentes a la acción de los inhibidores de los β-lactámicos. Dentro de las enterobacterias, las carbapenemasas se aíslan principalmente en K. pneumoniae y en menor medida en E. coli y otras especies, con una prevalencia más alta en el sur de Europa y Asia que en otras partes del mundo. Las carbapenemasas de la clase A, que pertenecen al grupo 2f de Bush-Jacoby, se pueden dividir en 5 grupos en base a su filogenética: GES, KPC, SME, IMI y NMCA. Las enzimas SME, NMC e IMI están codificadas en cromosómas mientras que las enzimas GES y KPC se encuentran codificadas en plásmidos. El gen blaKPC está asociado el transposón Tn4401. Clínicamente, el grupo que más interés tiene es el de las enzimas KPC. Existen 11 tipos descritos...

Analysis of the genome content of Lactococcus garvieae by genomic interspecies microarray hybridization

BACKGROUND Lactococcus garvieae is a bacterial pathogen that affects different animal species in addition to humans. Despite the widespread distribution and emerging clinical significance of L. garvieae in both veterinary and human medicine, there is almost a complete lack of knowledge about the genetic content of this microorganism. In the present study, the genomic content of L. garvieae CECT 4531 was analysed using bioinformatics tools and microarray-based comparative genomic hybridization (CGH) experiments. Lactococcus lactis subsp. lactis IL1403 and Streptococcus pneumoniae TIGR4 were used as reference microorganisms. RESULTS The combination and integration of in silico analyses and in vitro CGH experiments, performed in comparison with the reference microorganisms, allowed establishment of an inter-species hybridization framework with a detection threshold based on a sequence similarity of >or= 70%. With this threshold value, 267 genes were identified as having an analogue in L. garvieae, most of which (n = 258) have been documented for the first time in this pathogen. Most of the genes are related to ribosomal, sugar metabolism or energy conversion systems. Some of the identified genes, such as als and mycA, could be involved in the pathogenesis of L. garvieae infections. CONCLUSIONS In this study, we identified 267 genes that were potentially present in L. garvieae CECT 4531. Some of the identified genes could be involved in the pathogenesis of L. garvieae infections. These results provide the first insight into the genome content of L. garvieae.